Abstract

The Vector Core has undergone substantial evolution during the current cycle of the Center to leverage the tremendous progress that has been made in novel viral vectors. Dr. Julie Johnston, Director of Vector Core oversees the core with her tremendous experience in DNA and RNA viral Vectors. During the last four years, the list of services provided from the Vector Core has expanded exponentially. At the time of the last renewal of the grant the core provided services with vectors based on adenovirus serotype 5, adenoassociated virus (AAV) serotype 2 and murine based ecotropic and amphotropic retroviruses only. Currently the list of services provided by the core has expanded to include: Adenovirus - vectors based on human Ad5 and at least 5 simian adenoviruses with more novel simian adenoviruses in isolation;AAV- vectors based on the human AAV serotypes 1,2 and 5 and simian AAV serotype 7 and 8 with this list expanding to include 10 additional novel AAV serotypes over the next cycle of the grant;lentiviruses - at least 6 different pseudotypes based on HIV and FIV;and murine retroviruses with various pseudotypes. In addition to this increase in vector production it was very essential to quality assure these vectors. Currently there is a quality control group with Vector Core to check identity, potency and purity of any vector prep made in this unit.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK047757-20
Application #
8448742
Study Section
Special Emphasis Panel (ZDK1-GRB-1)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
20
Fiscal Year
2013
Total Cost
$361,447
Indirect Cost
$131,896

  Institution

Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104

  Publications

Svidritskiy, Egor; Korostelev, Andrei A (2018) Conformational Control of Translation Termination on the 70S Ribosome. Structure 26:821-828.e3
Svidritskiy, Egor; Korostelev, Andrei A (2018) Mechanism of Inhibition of Translation Termination by Blasticidin S. J Mol Biol 430:591-593
Gurda, Brittney L; De Guilhem De Lataillade, Adrien; Bell, Peter et al. (2016) Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII. Mol Ther 24:206-216
Svidritskiy, Egor; Madireddy, Rohini; Korostelev, Andrei A (2016) Structural Basis for Translation Termination on a Pseudouridylated Stop Codon. J Mol Biol 428:2228-36
Greig, Jenny A; Calcedo, Roberto; Grant, Rebecca L et al. (2016) Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 34:6323-6329
McClain, Lauren E; Davey, Marcus G; Zoltick, Phillip W et al. (2016) Vector serotype screening for use in ovine perinatal lung gene therapy. J Pediatr Surg 51:879-84
Calcedo, Roberto; Wilson, James M (2016) AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Hum Gene Ther Clin Dev 27:79-82
Svidritskiy, Egor; Korostelev, Andrei A (2015) Ribosome Structure Reveals Preservation of Active Sites in the Presence of a P-Site Wobble Mismatch. Structure 23:2155-61
Wang, Lili; Bell, Peter; Somanathan, Suryanarayan et al. (2015) Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol Ther 23:1877-87
Calcedo, Roberto; Franco, Judith; Qin, Qiuyue et al. (2015) Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Hum Gene Ther Methods 26:103-5

Showing the most recent 10 out of 231 publications